Tag: Wet

New EP1 Ratings Boost Vishay Wet Tantalum Capacitor Portfolio

Vishay Intertechnology VSH bolstered its wet tantalum capacitor offerings by adding new ratings in the B and C case codes to its EP1 capacitor.

Notably, the modified EP1 is based on the company’s SuperTan technology, which operates within a temperature of -55 °C to +85 °C. Also, it operates upto +125 °C, with voltage derating.

Further, the voltage ratings for the device lie between 25 VDC and 125 VDC. It also offers a standard capacitance tolerance of ± 20 %.

Additionally, EP1 now features high energy, very high-capacitance design, hermetically sealed case and all tantalum.

With all the features, EP1 provides ultra-high capacitance from 3,600 µF to 40,000 µF and 5,300 µF to 58,000 µF in the B and C case codes, respectively.

We believe that the enhanced EP1 is expected to add strength to the company’s passive component offerings.

Vishay Intertechnology, Inc. Price and Consensus

 

Vishay Intertechnology, Inc. Price and Consensus

Vishay Intertechnology, Inc. price-consensus-chart

Read More

Regenxbio: More Robust Data For Wet AMD (NASDAQ:RGNX)

The successful investor is usually an individual who is inherently interested in business problems. – Phillip Fisher (Warren Buffett’s mentor)

One of the hottest emerging areas in all of biotech is the gene therapy space. Using various techniques, companies developing gene therapies are either attempting to enhance or correct a defect in cells. To date, this has been achieved most successfully in the space of chimeric antigen receptor T-cells (CAR T-cells) in cancer therapy, where they’ve made a huge impact on the standard of care for certain kinds of leukemia.

What most people think of with gene therapy, however, is the delivery of “corrected” genes into the body, hoping to change the course of a disease. Hemophilia is a key recent example, with companies like Spark Therapeutics demonstrating a highly encouraging ability to get the liver to make correct clotting factors. It’s been a powerful proof of concept. Now, gene

Read More